Table 4.
Concordance of initial anti-MRSA therapy with practice guidelines
| Variable | Concordance, n=217 | Nonconcordance, n=28 | P-value |
|---|---|---|---|
| Anti-MRSA pharmaceutical | <0.01 | ||
| Vancomycin | 169 (97.1) | 5 (2.9) | |
| Teicoplanin | 4 (18.2) | 18 (81.8) | |
| Linezolid | 35 (92.1) | 3 (7.9) | |
| Daptomycin | 9 (81.8) | 2 (18.2) | |
| Drug substitution after initial treatment | 29 (13.4) | 11 (39.2) | <0.01 |
| Improvement in SOFA score | |||
| Day 0 to days 2–3 (n=244) | 138 (63.9) | 17 (60.7) | 0.74 |
| Days 2–3 to days 5–7 (n=243) | 148 (68.8) | 21 (75.0) | 0.50 |
| Newly acquired renal dysfunction | 31 (14.3) | 4 (14.2) | 1.00 |
| 30-day mortality, % | 12.9 | 7.1 | 0.38 |
Note: Unless specified otherwise, the values are numbers (%) of observations.
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; SOFA, sequential organ failure assessment.